Journal of Medicinal Chemistry · 2019 · 57 citations · 41 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryLead OptimizationStructure-activity RelationshipsComputational Drug DiscoveryEnzyme InhibitionLigand-based DesignPotency OptimizationQuantitative Structure-activity RelationshipsStructure-activity Relationship AnalysisChemical Series OptimizationChemical Structure-activity RelationshipsDrug Candidate OptimizationRelative Potency RatioSelectivity RatioStructure - Activity Relationship OptimizationStructure-activity Relationship ModelingStructure-based Ligand Design
A safer treatment for toxoplasmosis would be achieved by improving the selectivity and potency of dihydrofolate reductase (DHFR) inhibitors, such as pyrimethamine (1), for Toxoplasma gondii DHFR ( TgDHFR) relative to human DHFR ( hDHFR). We previously reported on the identification of meta-biphenyl analog 2, designed by in silico modeling of key differences in the binding pocket between TgDHFR and hDHFR. Compound 2 improves TgDHFR selectivity 6.6-fold and potency 16-fold relative to 1. Here, we report on the optimization and structure-activity relationships of this arylpiperazine series leading to the discovery of 5-(4-(3-(2-methoxypyrimidin-5-yl)phenyl)piperazin-1-yl)pyrimidine-2,4-diamine 3. Compound 3 has a TgDHFR IC
41
Handbook of clinical neurology
L S Illis · Spinal Cord · 2013 · 916 citations · Full text
Chunlei Su, Asis Khan, Peng Zhou et al. · Proceedings of the National Academy of Sciences · 2012 · 364 citations · Full text
Sandra K. Halonen, Louis M. Weiss · Handbook of clinical neurology · 2013 · 333 citations
Medicine, Dermatology, Immunology +17